A detailed history of Shell Asset Management CO transactions in Veracyte, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 8,957 shares of VCYT stock, worth $354,697. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,957
Previous 9,473 5.45%
Holding current value
$354,697
Previous $205,000 48.78%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$21.0 - $35.25 $10,836 - $18,189
-516 Reduced 5.45%
8,957 $305,000
Q1 2024

Jul 31, 2024

SELL
$21.0 - $29.1 $12,537 - $17,372
-597 Reduced 5.93%
9,473 $205,000
Q1 2024

May 14, 2024

BUY
$21.0 - $29.1 $123,228 - $170,758
5,868 Added 139.65%
10,070 $223,000
Q4 2023

Feb 14, 2024

SELL
$19.72 - $28.68 $23,782 - $34,588
-1,206 Reduced 22.3%
4,202 $116,000
Q3 2023

Nov 08, 2023

SELL
$22.33 - $29.92 $1,875 - $2,513
-84 Reduced 1.53%
5,408 $121,000
Q2 2023

Jul 28, 2023

SELL
$20.96 - $26.99 $670 - $863
-32 Reduced 0.58%
5,492 $140,000
Q1 2023

May 15, 2023

SELL
$20.58 - $27.89 $391 - $529
-19 Reduced 0.34%
5,524 $123,000
Q4 2022

Feb 07, 2023

SELL
$15.31 - $29.94 $6,659 - $13,023
-435 Reduced 7.28%
5,543 $132,000
Q3 2022

Nov 14, 2022

SELL
$16.58 - $27.9 $13,147 - $22,124
-793 Reduced 11.71%
5,978 $99,000
Q2 2022

Aug 09, 2022

BUY
$15.45 - $29.52 $71,842 - $137,268
4,650 Added 219.24%
6,771 $135,000
Q1 2022

May 04, 2022

SELL
$21.94 - $42.51 $7,042 - $13,645
-321 Reduced 13.14%
2,121 $58,000
Q4 2021

Feb 09, 2022

SELL
$36.09 - $53.79 $1,443 - $2,151
-40 Reduced 1.61%
2,442 $101,000
Q3 2021

Nov 04, 2021

SELL
$35.62 - $52.97 $3,561 - $5,297
-100 Reduced 3.87%
2,482 $115,000
Q1 2021

May 10, 2021

SELL
$44.47 - $81.38 $61,946 - $113,362
-1,393 Reduced 35.04%
2,582 $139,000
Q2 2020

Aug 10, 2020

BUY
$19.49 - $28.11 $77,472 - $111,737
3,975 New
3,975 $103,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.83B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.